![Patricia Andrews](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patricia Andrews
Direktor/Vorstandsmitglied bei
ONCOLYTICS BIOTECH INC.
Vermögen: 81 253 $ am 31.05.2026
Profil
Patricia S.
Andrews currently serves as Independent Non-Executive Director at Glenmark Pharmaceuticals Ltd. since 2025, Director at Geron Corp.
since 2026, Director at Ichnos Glenmark Innovation, Inc. since 2025, and Director at Oncolytics Biotech, Inc. since 2024.
Former positions include Chief Executive Officer at Sumitomo Pharma Oncology, Inc. from 2017 to 2023, Independent Director at GlycoMimetics, Inc., Chief Commercial Officer & Executive Vice President at Incyte Corp.
from 2009 to 2012, Vice President-Specialty Markets & General Manager at Pfizer Inc. in 2008, Global Head-Oncology at Sumitomo Pharma Co., Ltd. from 2017 to 2023, Chief Commercial Officer & Executive Vice President at Boston Biomedical, Inc. from 2013 to 2017, and Vice President-Capital Finance at HSBC Bank USA, NA in 1990.
Education includes undergraduate studies at Brown University and an MBA from the University of Michigan.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ONCOLYTICS BIOTECH INC. 0,07 % | 01.06.2026 | 78 128 ( 0,07 % ) | 81 253 $ | 31.05.2026 |
Aktive Positionen von Patricia Andrews
| Unternehmen | Position | Beginn |
|---|---|---|
| ONCOLYTICS BIOTECH INC. | Direktor/Vorstandsmitglied | 05.01.2024 |
| GLENMARK PHARMACEUTICALS LIMITED | Direktor/Vorstandsmitglied | 14.08.2025 |
| GERON CORPORATION | Direktor/Vorstandsmitglied | 25.03.2026 |
Ichnos Sciences, Inc.
 Ichnos Sciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops biologics in oncology | Direktor/Vorstandsmitglied | 01.08.2025 |
Ehemalige bekannte Positionen von Patricia Andrews
| Unternehmen | Position | Ende |
|---|---|---|
| SUMITOMO PHARMA CO., LTD. | Corporate Officer/Principal | 01.01.2023 |
SUMITOMO PHARMA ONCOLOGY, INC.
 SUMITOMO PHARMA ONCOLOGY, INC. BiotechnologyHealth Technology Provides biopharmaceutical research drug development services | Vorstandsvorsitzender | 01.01.2023 |
| INCYTE CORPORATION | Corporate Officer/Principal | 29.08.2012 |
| PFIZER INC. | Corporate Officer/Principal | 01.10.2008 |
HSBC Bank USA, NA
 HSBC Bank USA, NA Investment ManagersFinance HSBC Bank USA manages separate account and specializes in the use of asset allocation strategies. The firm's portfolio managers and analysts are generalists, although they do have significant investments in the stocks of small-cap European companies in the electronic technology sector. | Corporate Officer/Principal | 01.01.1990 |
Ausbildung von Patricia Andrews
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
98
Beziehungen ersten Grades
13
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
Sumitomo Pharma Co., Ltd.
 Sumitomo Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical and other chemical products | Health Technology |
Incyte Corp.
 Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Geron Corp.
 Geron Corp. BiotechnologyHealth Technology Discovers and develops therapeutic products for cancer | Health Technology |
Oncolytics Biotech, Inc.
 Oncolytics Biotech, Inc. BiotechnologyHealth Technology Discovers and develops pharmaceutical products for the treatment of cancers | Health Technology |
Boston Biomedical, Inc.
 Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Develops anticancer drugs | Commercial Services |
Brown University
 Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Glenmark Pharmaceuticals Ltd.
 Glenmark Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals | Health Technology |
HSBC Bank USA, NA
HSBC Bank USA, NA Investment ManagersFinance HSBC Bank USA manages separate account and specializes in the use of asset allocation strategies. The firm's portfolio managers and analysts are generalists, although they do have significant investments in the stocks of small-cap European companies in the electronic technology sector. | Finance |
University of Michigan
 University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlycoMimetics, Inc.
 GlycoMimetics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat inflammatory diseases and cancer | Health Technology |
Ichnos Sciences, Inc.
Ichnos Sciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops biologics in oncology | Health Technology |
SUMITOMO PHARMA ONCOLOGY, INC.
SUMITOMO PHARMA ONCOLOGY, INC. BiotechnologyHealth Technology Provides biopharmaceutical research drug development services | Health Technology |
Wählen Sie MarketScreener 
